$MYSZ
My Size, Inc. Stock $mysz

$mysz Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224019910 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$1.979M	$2.984M	$720.0K
YoY Change	53.41%	314.44%	80.0%
Cost Of Revenue	$995.0K	$1.788M	$1.147M
YoY Change	29.05%	55.88%	358.8%
Gross Profit	$984.0K	$1.196M	-$427.0K
YoY Change	89.6%	-380.09%	-1223.68%
Gross Profit Margin	49.72%	40.08%	-59.31%
Selling, General & Admin	$1.730M	$2.135M	$1.723M
YoY Change	-6.28%	23.91%	-6.66%
% of Gross Profit	175.81%	178.51%
Research & Development	$131.0K	$132.0K	$342.0K
YoY Change	-42.29%	-61.4%	-16.99%
% of Gross Profit	13.31%	11.04%
Depreciation & Amortization	$8.000K	$8.000K	$27.00K
YoY Change	-88.57%	-70.37%	-25.0%
% of Gross Profit	0.81%	0.67%
Operating Expenses	$1.861M	$2.267M	$2.065M
YoY Change	-10.23%	9.78%	-8.55%
Operating Profit	-$877.0K	-$1.071M	-$2.492M
YoY Change	-43.56%	-57.02%	18.38%
Interest Expense	-$87.00K	$55.00K	-$180.0K
YoY Change	-317.5%	-130.56%	125.0%
% of Operating Profit
Other Income/Expense, Net	-$87.00K	$55.00K	-$146.0K
YoY Change	-289.13%	-137.67%	75.9%
Pretax Income	-$964.0K	-$1.016M	-$2.672M
YoY Change	-36.29%	-61.98%	22.12%
Income Tax			-$18.00K
% Of Pretax Income
Net Earnings	-$964.0K	-$1.016M	-$2.654M
YoY Change	-25.33%	-61.72%	21.3%
Net Earnings / Revenue	-48.71%	-34.05%	-368.61%
Basic Earnings Per Share	-$1.28	-$1.88	-$1.68
Diluted Earnings Per Share	-$1.28	-$1.88	-$1.68
COMMON SHARES
Basic Shares Outstanding	641.5K shares	5.092M shares	2.447M shares
Diluted Shares Outstanding	755.6K shares	539.0K shares	197.8K shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.201M	$1.136M	$2.420M
YoY Change	183.27%	-53.06%	-69.13%
Cash & Equivalents	$3.201M	$1.136M	$2.415M
Short-Term Investments
Other Short-Term Assets	$74.00K	$75.00K	$260.0K
YoY Change	-38.33%	-71.15%	-3.7%
Inventory	$1.793M	$2.136M	$491.0K
Prepaid Expenses
Receivables	$329.0K	$406.0K	$1.008M
Other Receivables	$807.0K	$1.001M	$780.0K
Total Short-Term Assets	$6.204M	$4.754M	$4.953M
YoY Change	55.41%	-4.02%	-53.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$107.0K	$113.0K	$107.0K
YoY Change	-17.69%	5.61%	-89.19%
Goodwill	$733.0K	$741.0K	$1.412M
YoY Change	-47.75%	-47.52%
Intangibles	$919.0K	$996.0K	$1.313M
YoY Change	-25.16%	-24.14%
Long-Term Investments	$10.00K	$11.00K	$100.0K
YoY Change	-87.5%	-89.0%	11.11%
Other Assets	$7.000K	$7.000K	$30.00K
YoY Change	-76.67%	-76.67%	0.0%
Total Long-Term Assets	$1.808M	$1.916M	$3.515M
YoY Change	-45.25%	-45.49%	102.01%
TOTAL ASSETS
Total Short-Term Assets	$6.204M	$4.754M	$4.953M
Total Long-Term Assets	$1.808M	$1.916M	$3.515M
Total Assets	$8.012M	$6.670M	$8.468M
YoY Change	9.84%	-21.23%	-31.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$896.0K	$1.114M	$1.770M
YoY Change	-41.44%	-37.06%	-3.8%
Accrued Expenses	$17.00K	$53.00K	$160.0K
YoY Change	-88.67%	-66.88%	-11.11%
Deferred Revenue
YoY Change
Short-Term Debt	$423.0K	$582.0K	$158.0K
YoY Change	178.29%	268.35%	-31.3%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.109M	$2.699M	$2.851M
YoY Change	-32.12%	-5.33%	26.71%
LONG-TERM LIABILITIES
Long-Term Debt	$193.0K	$218.0K	$342.0K
YoY Change	-36.93%	-36.26%	144.29%
Other Long-Term Liabilities	$15.00K	$0.00	$300.0K
YoY Change	-92.5%	-100.0%	-41.18%
Total Long-Term Liabilities	$208.0K	$218.0K	$955.0K
YoY Change	-72.41%	-77.17%	46.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.109M	$2.699M	$2.851M
Total Long-Term Liabilities	$208.0K	$218.0K	$955.0K
Total Liabilities	$2.317M	$2.917M	$3.806M
YoY Change	-39.99%	-23.36%	27.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$61.86M	-$60.90M	-$56.16M
YoY Change	7.69%	8.44%
Common Stock	$1.000K	$1.000K	$2.000K
YoY Change	-50.0%	-50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.695M	$3.753M	$4.662M
YoY Change
Total Liabilities & Shareholders Equity	$8.012M	$6.670M	$8.468M
YoY Change	9.84%	-21.23%	-31.04%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$964.0K	-$1.016M	-$2.654M
YoY Change	-25.33%	-61.72%	21.3%
Depreciation, Depletion And Amortization	$8.000K	$8.000K	$27.00K
YoY Change	-88.57%	-70.37%	-25.0%
Cash From Operating Activities	-$659.0K	-$1.417M	-$2.313M
YoY Change	-50.45%	-38.74%	-10.31%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$60.00K	$0.00
YoY Change			-100.0%
Cash From Investing Activities	$0.00	$60.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.554M	$407.0K	$2.634M
YoY Change	-8613.33%	-84.55%	37528.57%
NET CHANGE
Cash From Operating Activities	-659.0K	-$1.417M	-$2.313M
Cash From Investing Activities	0.000	$60.00K
Cash From Financing Activities	2.554M	$407.0K	$2.634M
Net Change In Cash	1.895M	-$1.053M	$313.0K
YoY Change	-239.34%	-436.42%	-111.06%
FREE CASH FLOW
Cash From Operating Activities	-$659.0K	-$1.417M	-$2.313M
Capital Expenditures
Free Cash Flow			-$2.313M
YoY Change			-11.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	539042	shares
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	1788000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	1147000	usd
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001211805
CY2024Q1	MYSZ	Sort Term Deposit SortTermDeposit		usd
CY2024Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures		usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	MYSZ	Equity Loss Of Equity Method Investees EquityLossOfEquityMethodInvestees		usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	MYSZ	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants		usd
CY2024Q1	MYSZ	Increase Decrease In Investment In Joint Venture IncreaseDecreaseInInvestmentInJointVenture		usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities		usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments		usd
CY2023Q1	us-gaap	Proceeds From Hedge Investing Activities ProceedsFromHedgeInvestingActivities		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q1	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt		usd
CY2023Q1	MYSZ	Change In Operating Lease Rightofuse Asset And Liability ChangeInOperatingLeaseRightofuseAssetAndLiability		usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1136000	usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	75000	usd
CY2023Q4	MYSZ	Sort Term Deposit SortTermDeposit	22000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	2136000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	406000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1001000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	4754000	usd
CY2024Q1	us-gaap	Deposit Assets DepositAssets	7000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	113000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	48000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	996000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	741000	usd
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	24000	usd
CY2024Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	11000	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	1916000	usd
CY2024Q1	us-gaap	Assets Assets	6670000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	53000	usd
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	582000	usd
CY2024Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1114000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	73000	usd
CY2024Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	877000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2699000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	218000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	218000	usd
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1:8 reverse stock split
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4536000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	453000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	959000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6258000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	452724	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	452724	shares
CY2024Q1	us-gaap	Liabilities Liabilities	2917000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	641459	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	641459	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4536000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	101000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	35000	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	341000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2658000	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	65527000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-878000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60897000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3753000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6670000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2984000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	1196000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	-427000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	342000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1033000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	2267000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2065000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1071000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2492000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	55000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-146000	usd
CY2023Q1	MYSZ	Equity Loss Of Equity Method Investees EquityLossOfEquityMethodInvestees	34000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1016000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2672000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1016000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2654000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-107000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-15000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1123000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2669000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.88
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.88
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-13.42
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-13.42
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	539042	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	197794	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	197794	shares
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	643000	usd
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1:8 reverse stock split
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4735000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	138000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	3000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1123000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3753000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6258000	usd
CY2023Q1	MYSZ	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	1000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2669000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4662000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6514000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4735000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4735000	usd
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1:8 reverse stock split
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1016000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2654000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	8000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	27000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	98000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	31000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	76000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	74000	usd
CY2024Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-525000	usd
CY2023Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-23000	usd
CY2024Q1	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	8000	usd
CY2023Q1	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	6000	usd
CY2024Q1	us-gaap	Interest Paid InterestPaid	5000	usd
CY2023Q1	us-gaap	Interest Paid InterestPaid	6000	usd
CY2024Q1	MYSZ	Revaluation Of Investment In Marketable Securities RevaluationOfInvestmentInMarketableSecurities	5000	usd
CY2023Q1	MYSZ	Revaluation Of Investment In Marketable Securities RevaluationOfInvestmentInMarketableSecurities	-14000	usd
CY2023Q1	MYSZ	Increase Decrease In Investment In Joint Venture IncreaseDecreaseInInvestmentInJointVenture	34000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	138000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	136000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-742000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-481000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-18000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-209000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-903000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-47000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-37000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	150000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	30000	usd
CY2024Q1	MYSZ	Increase Decrease In Trade Payable IncreaseDecreaseInTradePayable	-1014000	usd
CY2023Q1	MYSZ	Increase Decrease In Trade Payable IncreaseDecreaseInTradePayable	-1403000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	66000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	152000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1417000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2313000	usd
CY2024Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	38000	usd
CY2024Q1	us-gaap	Proceeds From Hedge Investing Activities ProceedsFromHedgeInvestingActivities	22000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	60000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2659000	usd
CY2024Q1	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	500000	usd
CY2024Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	93000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	25000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	407000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2634000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-103000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-8000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1053000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	313000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2264000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2363000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1211000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2676000	usd
CY2024Q1	MYSZ	Change In Operating Lease Rightofuse Asset And Liability ChangeInOperatingLeaseRightofuseAssetAndLiability	181000	usd
CY2024Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1051000	usd
CY2024Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	2000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60897000	usd
CY2024Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	671000	usd
CY2024Q1	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	5000	usd
CY2023Q1	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	-14000	usd
CY2024Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	141000	usd
CY2023Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	136000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	(i) 5,000 shares of restricted common stock of the Company, (ii) a warrant to purchase 12,500 shares of common stock at an exercise price of $4.00 per share and exercisable for a term of 36 months from the date of issuance, and (iii) a warrant to purchase 12,500 shares of common stock at an exercise price of $6.00 per share and exercisable for a term of 36 months from the date of issuance.
CY2024Q1	us-gaap	Goodwill Goodwill	741000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	1412000	usd
CY2024Q1	us-gaap	Noncurrent Assets NoncurrentAssets	1897000	usd
CY2023Q1	us-gaap	Noncurrent Assets NoncurrentAssets	3454000	usd
CY2023Q4	us-gaap	Sale Of Stock Description Of Transaction SaleOfStockDescriptionOfTransaction	The Notification Letter provided that the Company had 180 calendar days, or until May 1, 2024, to regain compliance with the Rule. To regain compliance, the bid price of the Company’s common stock must have had a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. On May 7, 2024, the Company received a letter from Nasdaq that, for the 10 consecutive business days from April 23, 2024 to May 6, 2024, the closing bid price of the Company’s common stock had been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency matter now closed.
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-019910-index-headers.html	Edgar Link	pending
0001493152-24-019910-index.html	Edgar Link	pending
0001493152-24-019910.txt	Edgar Link	pending
0001493152-24-019910-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mysz-20240331.xsd	Edgar Link	pending
mysz-20240331_cal.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
mysz-20240331_lab.xml	Edgar Link	unprocessable
mysz-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
mysz-20240331_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MYSZ
My Size, Inc. Stock $mysz

2024 Q2 Form 10-Q Financial Statement

#000149315224019910 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MYSZ My Size, Inc. Stock $mysz

2024 Q2 Form 10-Q Financial Statement

#000149315224019910 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MYSZ
My Size, Inc. Stock $mysz